BridgeMD
Compares treatment options for Unresectable Hepatocellular Carcinoma
Official title TACE With Thermosensitive Nanogel Versus Embosphere for HCC
ClinicalTrials.gov ID: NCT06593964
What this study is testing
- What it's testing
- To verify the safety and efficacy of TACE withThermosensitive Nanogel Embolic Agent for HCC.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Chinese Liver Cancer Staging Scheme, stage IIb-Illa, as well as those with stage Ia-Ila HCC, unsuitable or unwilling to undergo surgical resection...
- Liver function status: Child-Pugh A or B
- Eastern Cooperative Oncology Group score: 0-2 points;
- With at least one measurable, unembolized liver tumor lesion (1-10 cm) ;
- Willing to participate in this trial and sign the informed consent.
You likely can't join if
- The target lesion has been embolized before or require combined with other treatment(s);
- Diffuse or with extrahepatic metastasis;
- Coagulation dysfunction (PT prolonged beyond the upper limit of normal for 3 seconds);
- Severe renal dysfunctions (creatinine clearance rate \<30 ml/min);
- Severe liver dysfunctions (alanine aminotransferase or aspartate aminotransferase exceeding the upper limit of normal by 5 times);
- Main portal vein was completely occluded and no collateral blood supply was established;
See the full eligibility criteria
- Chinese Liver Cancer Staging Scheme, stage IIb-Illa, as well as those with stage Ia-Ila HCC, unsuitable or unwilling to undergo surgical resection, transplantation, or ablation;
- Liver function status: Child-Pugh A or B
- Eastern Cooperative Oncology Group score: 0-2 points;
- With at least one measurable, unembolized liver tumor lesion (1-10 cm) ;
- Willing to participate in this trial and sign the informed consent.
- The target lesion has been embolized before or require combined with other treatment(s);
- Diffuse or with extrahepatic metastasis;
- Coagulation dysfunction (PT prolonged beyond the upper limit of normal for 3 seconds);
- Severe renal dysfunctions (creatinine clearance rate \<30 ml/min);
- Severe liver dysfunctions (alanine aminotransferase or aspartate aminotransferase exceeding the upper limit of normal by 5 times);
- Main portal vein was completely occluded and no collateral blood supply was established;
- With uncorrectable arteriovenous fistula or portal vein fistula;
- Severe cachexia or hepatic encephalopathy;
- With active infection;
- Significant reductions in white blood cells or platelets (white blood cells\<3.0x109/L, platelets\<50x109/L) that cannot be corrected;
- Pregnant or lactating women;
- Difficulty in selective catheterization;
- With the severe risk of non-target embolization;
- Severely allergic to contrast agents or the embolic materials;
- Participating in ongoing trial;
- Unsuitable judged by the investigator.
The study team makes the final eligibility decision.
Where it's taking place
- Nanjing, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Nanjing, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.